Kexing Biopharm's Oncology Product Abraxane Receives Marketing Approvals in Multiple Regions

Source: Cailian Press

【Kexing Biopharm【Albumin Paclitaxel, an Anti-Tumor Product, Obtains Marketing Approval in Multiple Regions】Cailian Press, March 9th: According to Kexing Biopharm, recently, Apexelsin®, the key anti-tumor product, injectable albumin-bound paclitaxel, co-developed by Kexing Biopharm and Haichang Biotech, has been granted marketing approval in Macao, China, and Malaysia. In addition, the production line of this product has successfully obtained the GMP certificate from the Turkish Medicines and Medical Devices Agency (TITCK). Apexelsin® has achieved several critical milestones in its global market access strategy, further expanding its sales regions.